Welcome to the CCO Site

Thank you for your interest in CCO content. As a guest, please complete the following information fields. These data help ensure our continued delivery of impactful education. 

Become a member (or login)? Member benefits include accreditation certificates, downloadable slides, and decision support tools.

Submit

Understanding the Therapeutic Antibody–Drug Conjugate Enfortumab Vedotin
  • CE

Credits Available
Pharmacists: 0.25 contact hours (0.025 CEUs)
Registered Nurses: 0.25 Nursing contact hours
Released: December 16, 2020 Expiration: December 15, 2021
Start Activity
Provided by Clinical Care Options, LLC.

Clinical Care Options, LLC
12001 Sunrise Valley Drive
Suite 300
Reston, VA

Sophia Kelley
(203)-316-2125
skelley@clinicaloptions.com
www.clinicaloptions.com

Supported by educational grants from
Janssen Biotech, Inc., administered by Janssen Scientific Affairs, LLC
Astellas and Seattle Genetics, Inc.
person default
Kinjal Patel, PharmD, BCOP
Susan Roethke, CRNP, MSN, AOCN, ANP-BC

Learning Objectives

Upon completion of this activity, participants should be able to:
  • Plan therapy for patients with urothelial carcinoma and disease progression during or following platinum-containing chemotherapy and/or immune checkpoint inhibitor therapy
  • Describe to patients and colleagues the available data and unique mechanisms of action of novel targeted therapies for the treatment of advanced urothelial carcinoma
  • Evaluate the toxicity profile as well as the pharmacokinetics and exposure-response association of approved antibody–drug conjugates in urothelial carcinoma
  • Identify patients appropriate for enrollment on ongoing clinical trials investigating targeted systemic therapies and novel combinations in urothelial carcinoma

Information on this Educational Activity

Clinical Care Options, LLC (CCO) requires instructors, planners, managers, and other individuals who are in a position to control the content of this activity to disclose any relevant conflict of interest (COI) they may have as related to the content of this activity. All identified COI are thoroughly vetted and resolved according to CCO policy. CCO is committed to providing its learners with high-quality CME/CE activities and related materials that promote improvements or quality in healthcare and not a specific proprietary business interest of a commercial interest.

The faculty reported the following financial relationships or relationships to products or devices they or their spouse/life partner have with commercial interests related to the content of this CME/CE activity:

Faculty

Kinjal Patel, PharmD, BCOP

Clinical Oncology Pharmacist
Department of Oncology
Fox Chase Cancer Center
Philadelphia, Pennsylvania

Kinjal Patel, PharmD, BCOP, has no relevant conflicts of interest to report.
Susan Roethke, CRNP, MSN, AOCN, ANP-BC

Nurse Practitioner
Department of Hematology/Oncology
Genitourinary Medical Oncology
Fox Chase Cancer Center
Temple Health
Philadelphia, Pennsylvania

Susan Roethke, CRNP, MSN, AOCN, ANP-BC has received fees for Non-CME/CE services from Astellas and Pfizer.

Staff

Kristen Rosenthal, PhD

Senior Scientific Director

Kristen M. Rosenthal, PhD, has no relevant conflicts of interest to report.
Timothy A. Quill, PhD

Associate Director, Scientific Services

Timothy A. Quill, PhD, has no relevant conflicts of interest to report.
June Wasserstrom

Director, CME Program Development

June Wasserstrom has no relevant conflicts of interest to report.
Jason Everly, PharmD

Director, Program Development and Educational Impact

Jason J. Everly, PharmD, BCOP, CHCP, has no relevant conflicts of interest to report.
Jim Mortimer

Senior Director, Oncology Programs and Partnership Development

Jim Mortimer has disclosed that his spouse/partner has received salary from AstraZeneca and has ownership interest in AstraZeneca
Kevin Obholz, PhD

Senior Director, Educational Strategy

Kevin Obholz, PhD, has no relevant conflicts of interest to report.

Disclosure of Unlabeled Use

This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this activity do not recommend the use of any agent outside of the labeled indications.

The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

Disclaimer

Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.

Target Audience

This program is intended for oncology infusion nurses, nurse practitioners, pharmacists, and other healthcare providers who manage the treatment of patients with urothelial carcinoma.

Goal

The goal of this activity is to improve the knowledge, competence, and performance of learners to apply the latest practice-changing data in the individualized clinical management of patients with locally advanced or metastatic urothelial carcinoma who have previously received a checkpoint inhibitor and a platinum-containing chemotherapy

Continuing Pharmacy Education

Credit Designation

CCO designates this continuing education activity for 0.25 contact hours (0.025 CEUs) of the Accreditation Council for Pharmacy Education. Universal Activity Number - JA4008176-0000-20-148-H02-P.

Type of Activity: Knowledge

Upon successfully completing the post-test with a score of 65% or better and the activity evaluation form, transcript information will be sent to the NABP CPE Monitor Service within 60 days.

Nursing Continuing Education

Credit Designation

The maximum number of hours awarded for this Continuing Nursing Education activity is 0.25 contact hours.

Program Medium

This program has been made available online.

Instructions for Credit

Participation in this self-study activity should be completed in approximately 0.25 hours. To successfully complete this activity and receive credit, participants must follow these steps during the period from December 16, 2020, through December 15, 2021:

1. Register online at http://www.clinicaloptions.com.
2. Read the target audience, learning objectives, and faculty disclosures.
3. Study the educational activity online or printed out.
4. Submit answers to the posttest questions and evaluation questions online.

You must receive a test score of at least 50% and respond to all evaluation questions to receive a certificate. After submitting the evaluation, you may access your online certificate by selecting the certificate link on the posttest confirmation page. Records of all CME/CE activities completed can be found on the "CME/CE Manager" page. There are no costs/fees for this activity.

Understanding the Therapeutic Antibody–Drug Conjugate Enfortumab Vedotin
  • CE

Loading...
Kinjal Patel, PharmD, BCOP, discusses the mechanism of action, indication and treatment considerations when using enfortumab vedotin for patients with advanced or metastatic urothelial carcinoma.
person default
Kinjal Patel, PharmD, BCOP
Susan Roethke, CRNP, MSN, AOCN, ANP-BC
Pharmacists: 0.25 contact hours (0.025 CEUs)
Registered Nurses: 0.25 Nursing contact hours
Released: December 16, 2020 Expiration: December 15, 2021

Related Content

Slides from Arjun Balar, MD on the role of biomarkers in managing urothelial cancer, from Clinical Care Options (CCO)

person default Arjun Balar, MD Released: April 21, 2021

Get expert insight from Arjun Balar, MD on the role of biomarkers in managing urothelial or bladder cancer, from Clinical Care Options (CCO)

person default Arjun Balar, MD person default Kaitlynn Francese, MSN, RN, OCN Physicians: maximum of 0.25 AMA PRA Category 1 Credits Registered Nurses: 0.25 Nursing contact hours Pharmacists: 0.25 contact hours (0.025 CEUs) Released: April 21, 2021 Expired: April 20, 2022

In this slideset from Clinical Care Options (CCO), experts provide insights on clinical trials of PARP inhibitor combinations in prostate cancer

Karim Fizazi, MD, PhD Joaquin Mateo, MD, PhD Released: April 19, 2021

In this slideset from Clinical Care Options (CCO), experts present the rationale for PARP inhibitor combination therapies in prostate cancer

Karim Fizazi, MD, PhD Joaquin Mateo, MD, PhD Released: April 16, 2021
Provided by Clinical Care Options, LLC.

Clinical Care Options, LLC
12001 Sunrise Valley Drive
Suite 300
Reston, VA

Sophia Kelley
(203)-316-2125
skelley@clinicaloptions.com
www.clinicaloptions.com

Supported by educational grants from
Janssen Biotech, Inc., administered by Janssen Scientific Affairs, LLC
Astellas and Seattle Genetics, Inc.

Leaving the CCO site

You are now leaving the CCO site. The new destination site may have different terms of use and privacy policy.

Continue